Kaposi Sarcoma

• EMA approval · 2026-04-24
  EMA Authorised: Caelyx pegylated liposomal (doxorubicin hydrochloride) — Baxter Holding B.V.

  EMA authorised Caelyx pegylated liposomal doxorubicin hydrochloride for Kaposi's sarcoma, multiple myeloma, ovarian cancer, and breast cance…

• EMA approval · 2026-04-16
  EMA Authorised: Zolsketil pegylated liposomal (doxorubicin hydrochloride, liposomal) — Accord Healthcare S.L.U.

  The EMA authorised Zolsketil pegylated liposomal doxorubicin for ovarian cancer, Kaposi sarcoma, and multiple myeloma. The Marketing Authori…

• FDA approval · 2025-11-17
  FDA Approved: PANRETIN — Supplemental Application (Advanz Pharma (US) Corp.)

  FDA approves Advanz Pharma US Corp's supplemental application for PANRETIN (alitretinoin). The approval may update labeling or add a new/exp…

• FDA approval · 2019-08-12
  FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)

  FDA approved a supplemental application for doxorubicin hydrochloride liposome submitted by Baxter Healthcare Company.

• FDA approval · 2016-08-23
  FDA Approved: PACLITAXEL PACLITAXEL — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)

  The FDA approved the original application for a generic paclitaxel product, manufactured by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmac…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-10-09
  FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)

  FDA approved Baxter's supplemental NDA for doxorubicin hydrochloride liposome.

• FDA approval · 2013-11-22
  FDA Approved: PANRETIN — Supplemental Application (Advanz Pharma (US) Corp.)

  FDA approved a supplemental application for PANRETIN (alitretinoin) filed by Advanz Pharma (US) Corp. The submission status is AP, indicatin…